New hope in cancer treatment: A 1-dollar drug!
India's TATA Institute has announced the development of a drug that could prevent cancer patients from relapsing and reduce the side effects of treatment by 50%.
12punto
12PUNTO FOREIGN NEWS
The TATA Institute in Mumbai, one of the world's largest and oldest cancer research centers, has announced the development of a cancer drug called 'R+Cu', which it states will have a market price of 100 rupees (1.2 dollars). It was stated that the drug reduces the side effects seen in patients receiving cancer treatment by 50%.
According to the institute's statement, the drug not only reduces the side effects of treatment but also lowers the risk of 'metastasis' in patients. Metastasis refers to the spread of cancer cells to other parts of the body. According to a report by The Economic Times, institute officials state that the drug also significantly reduces the risk of cancer recurrence in patients with a history of the disease.
R+Cu, which the TATA Institute has been working on for ten years, contains 'oxygen radicals' that fight cancer, such as resveratrol and copper. These radicals prevent dying cancer cells from affecting healthy cells and turning them cancerous.
Researchers suggest that the drug could be effective in the treatment of pancreatic, lung, and oral cancers.
The drug developed by TATA will be one of the cheapest cancer drugs on the market. According to the institute's statement, the price set for the drug is 1.2 dollars. R+Cu is expected to receive approval from the Food Safety and Standards Authority of India (FSSAI) in the summer months. The drug has been tested on mice and humans so far. It is believed that the FSSAI will grant approval for the release of R+Cu once definitive test results regarding the drug's side effects are obtained.